Juha-Pekka Erälinna

Medicine · Health Sciences

19h-index2.7kcitations39works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(19), Peripheral Neuropathies and Disorders(8), Systemic Lupus Erythematosus Research(7), Immunotherapy and Immune Responses(5), Polyomavirus and related diseases(5)

Publications35 total

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression
Neurology·2025· 1 citedOpen Access
Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with a Suboptimal Response to Previous Disease-Modifying Therapies (1-Year Interim Results)
Multiple Sclerosis and Related Disorders·2020Open Access
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results)
Journal of the Neurological Sciences·2019· 1 cited
Efficacy and Safety of 2 Doses of Ponesimod (10 and 20 mg o.d.): Interim Analysis of a Phase II Extension Trial in Relapsing-remitting Multiple Sclerosis (P3.398)
Neurology·2018· 2 cited
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
The Lancet Neurology·2018· 327 citedOpen Access
Painless legs and moving toes associated with acute axonal sensory polyneuropathy
Basal Ganglia·2016
Progressiivinen multifokaalinen leukoenkefalopatia natalitsumabihoidon komplikaationa
Tampere University Institutional Repository (Tampere University)·2015· 1 citedOpen Access
[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
PubMed·2013· 5 cited
MS-tauti : Käypä hoito -suosituksen päivitystiivistelmä
2013
MS-taudin diagnoosi, lääkehoito ja kuntoutus
Tampere University Institutional Repository (Tampere University)·2012
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
The Lancet Neurology·2011· 116 cited
Temporal relationship between environmental influenza A and Epstein–Barr viral infections and high multiple sclerosis relapse occurrence
Multiple Sclerosis Journal·2011· 62 cited
[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
PubMed·2010· 1 cited
[Vaccinations and neurological disease].
PubMed·2010· 1 cited
MxA protein assay for optimal monitoring of IFN-β bioactivity in the treatment of MS patients
Acta Neurologica Scandinavica·2008· 22 cited
Beta-Interferon Protects Multiple Sclerosis Patients against Enhanced Susceptibility to Infections Caused by Poor Air Quality
Neuroepidemiology·2008· 17 cited
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
Neurology·2006· 255 cited
MxA protein induction in MS patients treated with intramuscular IFNβ-1a
Neurological Sciences·2006· 5 cited
Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy
International Immunopharmacology·2006· 4 cited
[Not Available].
PubMed·2006
page 1 of 2Next →

Frequent Co-authors

A. Salmi(14), Matias Röyttä(9), Irina Elovaara(7), Veijo Hukkanen(7), Merja Soilu‐Hänninen(6), R. Salonen(5), Martti Färkkilâ(5), Juhani Ruutiainen(5), M. Panelius(4), Anna-Maija Vallittu(4), Jutta Peltoniemi(4), Jorma Ilonen(4), Eeva Broberg(4), Niko Setälä(4), Tuula Pirttilä(4), Pirkko Sonninen(3), Eva Havrdová(3), Finn Sellebjerg(3), Jette Lautrup Frederiksen(3), Mervi Oikonen(3)